CSMG Technologies Announces U.S. FDA 510(k) Clearance for Live Tissue Connect's VAD...

CSMG Technologies Announces U.S. FDA 510(k) Clearance for Live Tissue Connect's VAD System

CORPUS CHRISTI, Texas--(Business Wire)--
CSMG Technologies, Inc., (OTCBB: CTGI), a technology management
company, announced its subsidiary Live Tissue Connect, Inc. (LTC)
received 510(k) clearance from the U.S. Food and Drug Administration
(FDA) to market its LTC VAD System. The LTC VAD System consists of a
LTC VAD.400 bipolar electrosurgical generator and two disposable
sealing instruments. FDA clearance allows LTC to market these products
in the USA.

The VAD.400 generator and the two disposable instruments are
intended for use in open general surgical and gynecological procedures
for the ligation of vessels and ducts as an alternative to mechanical
clamping (clips or staples) and suturing. LTC's new third generation
bipolar system can be used on vessels (veins and arteries) up to 7 mm
diameter, on ducts up to 2 mm diameter and tissue bundles as large as
will fit in the jaw electrodes of the instruments.

Donald S. Robbins, President and CEO of CSMG Technologies, said,
"I am very pleased for our shareholders to be able to announce the
most important and long awaited event in the history of LTC. By LTC
receiving its first U.S. FDA 510(k) on the generator and the two
instruments they are now able to start marketing in the U.S. market. I
wish to publicly congratulate all the medical device professions
involved with the LTC technology and the LTC team in Santa Barbara,
California. I also want to personally thank as well all the CSMG
shareholders who have believed in our potential and stayed the course
waiting for this key corporate event."

Frank D. D'Amelio, President of LTC said, "The 510(k) clearance of
our generator and disposable instruments marks the completion of a
major milestone for LTC. The technology embodied within the VAD.400
generator and the interconnecting disposable instruments represents
years of scientific research regarding the effects of RF energy on
tissue. The LTC bipolar system has undergone extensive animal clinical
testing; has been the subject to numerous peer-reviewed papers; and
has passed all applicable quality standards. Having now obtained this
clearance, we will next implement our USA sales representative
recruitment plan and ramp up our production for distribution."

About Live Tissue Connect

LTC's surgical tissue bonding / welding device is a patented
platform technology that bonds and reconnects human soft tissue
through fusion, in contrast with conventional wound closing devices
such as sutures, staples, sealant, or glues. LTC currently holds a
total of approximately 31 patents and pending patents in the U.S.,
Australia, Canada, European Union, Ukraine and other countries.

For further information on CSMG Technologies and its various
subsidiaries, please visit our website at
www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press
releases and other notifications: Please go to:
www.csmgtechinternational.com/contact_information.html and fill-in
information.

This press release may contain forward-looking information within
the meaning of Section 21E of the Securities Exchange Act of 1934 as
amended (the Exchange Act), including all statements that are not
statements of historical fact regarding the intent, belief or current
expectations of the company, its directors or its officers with
respect to, among other things: (i) the company's financing plans;
(ii) trends affecting the company's financial condition or results of
operations; (iii) the company's growth strategy and operating
strategy; and (iv) the declaration and payment of dividends. The words
"may," "would," "will," "expect," "estimate," "anticipate," "believe,"
"intend" and similar expressions and variations thereof are intended
to identify forward-looking statements. Investors are cautioned that
any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, many of which are
beyond the company's ability to control, and that actual results may
differ materially from those projected in the forward-looking
statements as a result of various factors.

ROI Group LLC
Michael Dodge, 212-495-0744
mdodge@roiny.com
or
CSMG Technologies, Inc.
Donald S. Robbins, 361-887-754
President and CEO
or
K. Bruce Jones, 770-955-0409

Copyright Business Wire 2008